This report was finalized prior to a significant development affecting the central thesis, and readers are advised to take that into account.
On July 17, 2026, GSK announced the discontinuation of camlipixant's Phase III development program in refractory chronic cough (RCC), the asset identified throughout this report as the leading candidate for first FDA approval in the indication.
The CALM-1 and CALM-2 trials produced mixed results: the 50mg twice-daily dose met its primary endpoint of statistically significant 24-hour cough frequency reduction versus placebo in CALM-1 (week 12), but failed to reach significance on the same measure in CALM-2 (week 24); the 25mg dose did not achieve significance in either study. Key secondary endpoints, including the Chronic Cough Diary measure, missed target thresholds across both trials. GSK stated that, "based on the aggregate data, the limited efficacy demonstrated is unlikely to transform patient care," and confirmed it will not progress camlipixant further in RCC.
This outcome removes the pipeline's most advanced asset and leaves the RCC indication without a late-stage P2X3 antagonist in active development, following gefapixant's earlier U.S. regulatory setbacks. It resets the competitive landscape, approval timeline, and market-creation trajectory presented in this report.
Readers are advised to treat all forward-looking analyses, valuation, and share-capture estimates tied to camlipixant as superseded.